Stocktoria

IN8BIO, INC. INAB

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-12 · LEI

IN8BIO, INC. statistics & valuation

Market cap$13.4M
P / B0.5×
Return on equity-70.5%
Return on capital-66.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
202020212022202320242025
Return on equity (%)
-125.50% -120.30% -210.20% -70.50% 202020212022202320242025
Shares outstanding
3.8M 18.8M 24.5M 43.3M 2.4M 9.8M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-40.90% -34.70% -86.30% -89.00% -145.30% -60.20% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$1.47 -$1.36 -$1.00 -$17.05 -$4.44 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-60.2%-145.3%-89.0%-86.3%-34.7%-40.9%
Return on equity-70.5%-210.2%-120.3%-125.5%38.4%51.6%
Current ratio8.824.084.573.8217.287.05

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.